U-Blot® Research Grade Anti-Human CD269/TNFRSF17/BCMA (HDP-101)Cat. No. WA1492Request quote
Size: 50ug/100ug
Biosimilar antibodies are developed strictly against reference therapeutic mAbs. Validated through multi-dimensional physicochemical, functional and clinical studies, they exhibit highly consistent efficacy and safety profiles compared with originator products, featuring cost advantages and stable lot-to-lot quality.
U-Blot® Research Grade Anti-Human CD269/TNFRSF17/BCMA (HDP-101)Cat. No. WA1492
U-Blot® Research Grade Anti-Human CD269/TNFRSF17/BCMA (CT053)Cat. No. WA1491
U-Blot® Research Grade Anti-Human CD269/TNFRSF17/BCMA (AMG 224)Cat. No. WA1490
U-Blot® Research Grade Anti-Human CD269/TNFRSF17/BCMA (ALLO-605)Cat. No. WA1489
U-Blot® Research Grade Anti-Human CD266/TNFRSF12A (RO-5458640)Cat. No. WA1488
U-Blot® Research Grade Anti-Human CD266/TNFRSF12A (BIIB036)Cat. No. WA1487
U-Blot® Research Grade Anti-Human CD266/TNFRSF12A (BAY-356)Cat. No. WA1486
U-Blot® Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (TAS266)Cat. No. WA1485
U-Blot® Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (LBY135)Cat. No. WA1484
U-Blot® Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (INBRX-109)Cat. No. WA1483
U-Blot® Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (IGM 8444)Cat. No. WA1482
U-Blot® Research Grade Anti-Human CD262/TNFRSF10B/TRAIL-R2/DR5 (DS-8273a)Cat. No. WA1481